4.5 Article

A constitutively active and uninhibitable caspase-3 zymogen efficiently induces apoptosis

Journal

BIOCHEMICAL JOURNAL
Volume 424, Issue -, Pages 335-345

Publisher

PORTLAND PRESS LTD
DOI: 10.1042/BJ20090825

Keywords

apoptosis; cancer therapy; conformational switch; co-operative dimer interface; procaspase activation

Funding

  1. NIH [GM065970, CA096867]
  2. U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences [W-31-109-ENG-38]

Ask authors/readers for more resources

The caspase-3 zymogen has essentially zero activity until it is cleaved by initiator caspases during apoptosis. However, a mutation of V266E in the dimer interface activates the protease in the absence of chain cleavage. We show that low concentrations of the pseudo-activated procaspase-3 kill mammalian cells rapidly and, importantly, this protein is not cleaved nor is it inhibited efficiently by the endogenous regulator XIAP (X-linked inhibitor of apoptosis). The 1.63 angstrom (1 angstrom = 0.1 nm) structure of the variant demonstrates that the mutation is accommodated at the dimer interface to generate an enzyme with substantially the same activity and specificity as wild-type caspase-3. Structural modelling predicts that the interface mutation prevents the intersubunit linker from binding in the dimer interface, allowing the active sites to form in the procaspase ill the absence of cleavage. The direct activation of procaspase-3 through a conformational switch rather than by chain cleavage C, may lead to novel therapeutic strategies for inducing cell death.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available